Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease

World Health Organization, 2016 McGarry, 1992, What if Minkowski had been ageusic? An alternative angle on diabetes, Science (Wash. DC), 258, 766, 10.1126/science.1439783 Randle, 1963, The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, Lancet, i, 785, 10.1016/S0140-6736(63)91500-9 Kalra, 2013, Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT), J Assoc Phys India, 61, 448 Tolman, 2007, Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease, Diabetes Care, 30, 734, 10.2337/dc06-1539 Chapman, 2013, Macrovascular disease in the elderly with type 1 diabetes, J Diabetes Metabol, 4, 299 Trombetta, 2005, Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study, Aliment Pharmacol Ther, 22, 24, 10.1111/j.1365-2036.2005.02590.x Fruci, 2013, Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment, Int J Mol Sci, 14, 22933, 10.3390/ijms141122933 E1, 2005, Insulin resistance: a metabolic pathway to chronic liver disease, Hepatology, 42, 987, 10.1002/hep.20920 Lehninger, 2005 Saltiel, 2001, Insulin signalling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a Perry, 2014, The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes, Nature, 510, 84, 10.1038/nature13478 Angulo, 2007, GI epidemiology: nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 25, 883, 10.1111/j.1365-2036.2007.03246.x Gaggini, 2013, Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease, Nutrients, 5, 1544, 10.3390/nu5051544 Jung, 2016, Apigenin ameliorates dyslipidemia, hepatic steatosis and insulin resistance by modulating metabolic and transcriptional profiles in the liver of high-fat diet-induced obese mice, Nutrients, 8, 305, 10.3390/nu8050305 Harriman, 2016, Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats, Proc Natl Acad Sci Unit States Am, 113, E1796, 10.1073/pnas.1520686113 Kelley, 2003, Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance, Am J Physiol Endocrinol Metab, 285, E906, 10.1152/ajpendo.00117.2003 Gary-Bobo, 2007, Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, 46, 122, 10.1002/hep.21641 Lucchesi, 2013, Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease, Acta Cir Bras, 28, 502, 10.1590/S0102-86502013000700005 Aldahmash, 2016, Attenuation of hepatotoxicity and oxidative stress in diabetes STZ-induced type 1 by biotin in Swiss albino mice, Saudi J Biol Sci, 23, 311, 10.1016/j.sjbs.2015.09.027 Oguntibeju, 2016, Hypoxis hemerocallidea significantly reduced hyperglycaemia and hyperglycaemic-induced oxidative stress in the liver and kidney tissues of streptozotocin-induced diabetic male wistar rats, Evid Base Compl Alternative Med, 1 Krishan, 2017, Carbohydrate restriction ameliorates nephropathy by reducing oxidative stress and upregulating HIF-1α levels in type-1 diabetic rats, J Diabetes Metab Disord, 16, 47, 10.1186/s40200-017-0331-5 Larsen, 2010, Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults, PLoS One, 5, e9085, 10.1371/journal.pone.0009085 Takamatsu, 2008, Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma, Hepatogastroenterology, 55, 609 Harrison, 2008, Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment, Clin Gastroenterol Hepatol, 6, 864, 10.1016/j.cgh.2008.03.024 Marchesini, 2007, Metabolic syndrome and NASH, Clin Liver Dis, 11, 105, 10.1016/j.cld.2007.02.013 Wan, 2016, Role of stem cells during diabetic liver injury, J Cell Mol Med, 20, 195, 10.1111/jcmm.12723 Fiorentino, 2016, One-hour post-load hyperglycemia confers higher risk of hepatic steatosis to HbA1c-defined pre-diabetic subjects, J Clin Endocrinol Metab, 101, 4030, 10.1210/jc.2016-1856 Bambha, 2014, Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis, Liver Int, 34, 1250, 10.1111/liv.12379 Siddiqui, 2015, Nonalcoholic steatohepatitis (nash) is associated with a decline in pancreatic beta cell (β-cell) function, Dig Dis Sci, 60, 2529, 10.1007/s10620-015-3627-7 Tai, 2016, Solanum nigrum protects against hepatic fibrosis via suppression of hyperglycemia in high-fat/ethanol diet-induced rats, Molecules, 21, 269, 10.3390/molecules21030269 Liu, 2016, 1-Deoxynojirimycin alleviates liver injury and improves hepatic glucose metabolism in db/db mice, Molecules, 21, 279, 10.3390/molecules21030279 Xu, 2016, Canine Fibroblast growth factor 21 ameliorates hyperglycemia associated with inhibiting hepatic gluconeogenesis and improving pancreatic beta-cell survival in diabetic mice and dogs, PLoS One, 11, e0155598, 10.1371/journal.pone.0155598 Sáez-Lara, 2016, Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials, Int J Mol Sci, 17, 928, 10.3390/ijms17060928 Everard, 2013, Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity, Proc Natl Acad Sci USA, 110, 9066, 10.1073/pnas.1219451110 Shin, 2014, An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice, Gut, 63, 727, 10.1136/gutjnl-2012-303839 Malaguarnera, 2012, Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis, Dig Dis Sci, 57, 545, 10.1007/s10620-011-1887-4 Mencarelli, 2012, VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation, PLoS One, 7, e45425, 10.1371/journal.pone.0045425 Sanduzzi Zamparelli, 2016, The metabolic role of gut microbiota in the development of nonalcoholic fatty liver disease and cardiovascular disease, Int J Mol Sci, 17, 1225, 10.3390/ijms17081225 Lillioja, 1993, Insulin resistance as precursor of non-insulin dependent diabetes mellitus. Prospective studies of Pima Indians, N Engl J Med, 329, 1988, 10.1056/NEJM199312303292703 Boden, 1997, Role of fatty acids in the pathogenesis of insulin resistance and NIDDM, Diabetes, 46, 3, 10.2337/diab.46.1.3 Randle, 1965, The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus, Ann NY Acad Sci, 131, 324, 10.1111/j.1749-6632.1965.tb34800.x Wu, 2011, Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes, Proc Natl Acad Sci USA, 108, 5378, 10.1073/pnas.1002588108 Williamson, 2011, Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study, Diabetes Care, 34, 1139, 10.2337/dc10-2229 Bergman, 2000, Free fatty acids and pathogenesis of type 2 diabetes mellitus, Trends Endocrinol Metabol, 11, 351, 10.1016/S1043-2760(00)00323-4 Shulman, 2000, Cellular mechanisms of insulin resistance, J Clin Invest, 106, 171, 10.1172/JCI10583 Bhatt, 2015, Fatty liver disease in diabetes mellitus, Hepatobiliary Surg Nutr, 4, 101 Bugianesi, 2005, Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms, Diabetologia, 48, 634, 10.1007/s00125-005-1682-x Haukeland, 2012, Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies, Eur J Endocrinol, 166, 503, 10.1530/EJE-11-0864 Sato, 2015, Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects, Liver Int, 35, 925, 10.1111/liv.12478 Trepanowski, 2015, Fetuin-A: a novel link between obesity and related complications, IJO, 39, 734 Ban, 2008, Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers, Vasc Health Risk Manag, 4, 575, 10.2147/VHRM.S1991 Bastard, 2006, Recent advances in the relationship between obesity, inflammation, and insulin resistance, Eur Cytokine Netw, 17, 4 Kristiansen, 2005, Interleukin-6 and diabetes: the good, the bad, or the indifferent?, Diabetes, 54, 114, 10.2337/diabetes.54.suppl_2.S114 Wan, 2016, Role of stem cells during diabetic liver injury, J Cell Mol Med, 20, 195, 10.1111/jcmm.12723 Tilg, 2010, The role of cytokines in non-alcoholic fatty liver disease, Dig Dis, 28, 179, 10.1159/000282083 Solomon, 2010, TNF-alpha inhibits insulin action in liver and adipose tissue: a model of metabolic syndrome, Horm Metab Res, 42, 115, 10.1055/s-0029-1241834 Labudzynskyi, 2016, Role of vitamin D3 in regulation of interleukin-6 and osteopontin expression in liver of diabetic mice, Diabetes, 37, 22 Le, 2004, Chemokines and chemokine receptors: their manifold roles in homeostasis and disease" (PDF), Cell Mol Immunol, 1, 95 Sindhu, 2017, Increased circulatory levels of fractalkine (CX3CL1) are associated with inflammatory chemokines and cytokines in individuals with type-2 diabetes, J Diabetes Metab Disord, 16, 15, 10.1186/s40200-017-0297-3 Wehr, 2014, Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury, PLoS One, 9, e112327, 10.1371/journal.pone.0112327 Andrade-Oliveira, 2015, Adipokines as drug targets in diabetes and underlying disturbances, J Diabetes Res, 1 Diehl, 2004, Obesity and alcoholic liver disease, Alcohol, 34, 81, 10.1016/j.alcohol.2004.07.010 Marra, 2011, Modulation of liver fibrosis by adipokines, Dig Dis, 29, 371, 10.1159/000329799 Novo, 2014, Cellular and molecular mechanisms in liver fibrogenesis, Arch Biochem Biophys, 548, 20, 10.1016/j.abb.2014.02.015 Matsuzawa, 2010, Adiponectin: a key player in obesity related disorders, Curr Pharmaceut Des, 16, 1896, 10.2174/138161210791208893 Liu, 2007, Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes, Endocrinology, 148, 683, 10.1210/en.2006-0708 Xie, 2006, Intracellular trafficking and secretion of adiponectin is dependent on GGA-coated vesicles, J Biol Chem, 281, 7253, 10.1074/jbc.M511313200 Halaas, 1995, Weight-reducing effects of the plasma protein encoded by the obese gene, Science, 269, 543, 10.1126/science.7624777 Li, 2013, Adipokines and hepatic insulin resistance, J Diabetes Res, 1 Uemura, 2001, Diabetes mellitus enhances vascular matrix metalloproteinase activity role of oxidative stress, Circ Res, 88, 1291, 10.1161/hh1201.092042 Koneru, 2017, Polydatin alleviates alcohol-induced acute liver injury in mice: relevance of matrix metalloproteinases (MMPs) and hepatic antioxidants, Phytomedicine, 27, 23, 10.1016/j.phymed.2017.01.013 Chen, 2016, Gossypol ameliorates liver fibrosis in diabetic rats induced by high-fat diet and streptozocin, Life Sci, 149, 58, 10.1016/j.lfs.2016.02.044 Hou, 2014, Alteration of liver MMP-9/TIMP-1 and plasma type IV collagen in the development of rat insulin resistance, 531 Fracanzani, 2008, The risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002/hep.22429 Dongiovanni, 2010, Genetic variants regulating Insulin Receptor signaling are associated with the severity of liver damage in patients with nonalcoholic fatty liver disease, Gut, 59, 267, 10.1136/gut.2009.190801 Kohjima, 2007, Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease, Int J Mol Med, 20, 351 Dorn, 2010, Expression of fatty acid synthase in nonalcoholic fatty liver, Int J Clin Exp Pathol, 3, 505 Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, 1461, 10.1038/ng.257 Nakae, 1999, Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway, J Biol Chem, 274, 15982, 10.1074/jbc.274.23.15982 McGettrick, 2005, Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation, J Biol Chem, 280, 6441, 10.1074/jbc.M412300200 Li, 2011, AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice, Cell Metabol, 13, 376, 10.1016/j.cmet.2011.03.009 Weedon, 2003, Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility, Am J Hum Genet, 73, 1208, 10.1086/379285 Hamed, 2015, Managing diabetes and liver disease association, guidelines (consensus) development, J Endocrinol Diabetes Obes, 3, 1 Armstrong, 2013, Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program, Aliment Pharmacol Ther, 37, 234, 10.1111/apt.12149 Ohki, 2012, The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone, Sci World J, 1, 10.1100/2012/496453 Gouni-Berthold, 2014, The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease, Curr Pharmaceut Des, 20, 3705, 10.2174/13816128113196660676 Komiya, 2016, Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction, PLoS One, 11, e0151511, 10.1371/journal.pone.0151511 Moslehi, 2016, Naltrexone changes the expression of lipid metabolism-related proteins in the endoplasmic reticulum (ER) stress induced hepatic steatosis in mice, Clin Exp Pharmacol Physiol, 44, 207, 10.1111/1440-1681.12695 Li, 2016, Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, ER stress and lipogenesis and is regulated by HNF4α, Hepatology, 63, 1860, 10.1002/hep.28472 Newberry, 2016, Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in Liver fatty acid binding protein null mice, Hepatology, 65, 836, 10.1002/hep.28941 Gong, 2016, Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1, Hepatology, 64, 425, 10.1002/hep.28523 Mazzotti, 2016, Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?, Dig Liver Dis, 49, 235, 10.1016/j.dld.2016.12.028 Kuchay, 2018, Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial), Diabetes Care, 1 Staels, 2013, Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, Hepatology, 58, 1941, 10.1002/hep.26461 Al-muzafar, 2017, Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers, BMC Compl Alternative Med, 17, 43, 10.1186/s12906-016-1540-z Yokohama, 2016, Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice, Int J Mol Med, 38, 1499, 10.3892/ijmm.2016.2766 Lee, 2017, Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness, J Kor Med Sci, 32, 60, 10.3346/jkms.2017.32.1.60 Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 Hoofnagle, 2013, Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 38, 134, 10.1111/apt.12352 Hemant Thacker, 2016, Novel action of saroglitazar in patients with diabetic dyslipidemia-an observational study, Endod Pract, 22, 183, 10.1016/S1530-891X(20)45176-6